Topical Roflumilast for Plaque Psoriasis
Skin Therapy Lett. 2023 Sep;28(5):1-4.ABSTRACTRoflumilast is a highly selective phosphodiesterase-4 inhibitor for the treatment of plaque psoriasis. Topical roflumilast 0.3% cream, approved by the US FDA and Health Canada for use in adolescents and adults, has proven efficacy and tolerability. It is non-steroidal, administered once-daily, and highly potent, with a unique delivery formulation. It can be used on most body areas, including the sensitive intertriginous regions and face. Herein, we review the safety and efficacy of roflumilast 0.3% cream, as demonstrated in clinical trials.PMID:37734074 (Source: Skin Therapy Letter)
Source: Skin Therapy Letter - September 21, 2023 Category: Dermatology Authors: Ashley O'Toole Melinda Gooderham Source Type: research
A Practical Guide to Advanced Topical Drug Delivery Systems in Dermatology
Skin Therapy Lett. 2023 Sep;28(5):5-11.ABSTRACTDermatological diseases such as atopic dermatitis, acne, and psoriasis result in significant morbidity and decreased quality of life. The first line of treatment for such diseases is often topical medications. While topical delivery allows active drug to be delivered directly to the target site, the skin is a virtually impermeable barrier that impedes delivery of large molecules. Thus, the formulation and delivery system are integral elements of topical medications. Patients also have preferences for the properties of topical formulations and these preferences can positively o...
Source: Skin Therapy Letter - September 21, 2023 Category: Dermatology Authors: Andrei Metelitsa Isabelle Delorme Daniel O'Sullivan Rami Zeinab Mark Legault Melinda Gooderham Source Type: research
Topical Roflumilast for Plaque Psoriasis
Skin Therapy Lett. 2023 Sep;28(5):1-4.ABSTRACTRoflumilast is a highly selective phosphodiesterase-4 inhibitor for the treatment of plaque psoriasis. Topical roflumilast 0.3% cream, approved by the US FDA and Health Canada for use in adolescents and adults, has proven efficacy and tolerability. It is non-steroidal, administered once-daily, and highly potent, with a unique delivery formulation. It can be used on most body areas, including the sensitive intertriginous regions and face. Herein, we review the safety and efficacy of roflumilast 0.3% cream, as demonstrated in clinical trials.PMID:37734074 (Source: Skin Therapy Letter)
Source: Skin Therapy Letter - September 21, 2023 Category: Dermatology Authors: Ashley O'Toole Melinda Gooderham Source Type: research
A Practical Guide to Advanced Topical Drug Delivery Systems in Dermatology
Skin Therapy Lett. 2023 Sep;28(5):5-11.ABSTRACTDermatological diseases such as atopic dermatitis, acne, and psoriasis result in significant morbidity and decreased quality of life. The first line of treatment for such diseases is often topical medications. While topical delivery allows active drug to be delivered directly to the target site, the skin is a virtually impermeable barrier that impedes delivery of large molecules. Thus, the formulation and delivery system are integral elements of topical medications. Patients also have preferences for the properties of topical formulations and these preferences can positively o...
Source: Skin Therapy Letter - September 21, 2023 Category: Dermatology Authors: Andrei Metelitsa Isabelle Delorme Daniel O'Sullivan Rami Zeinab Mark Legault Melinda Gooderham Source Type: research
Topical Roflumilast for Plaque Psoriasis
Skin Therapy Lett. 2023 Sep;28(5):1-4.ABSTRACTRoflumilast is a highly selective phosphodiesterase-4 inhibitor for the treatment of plaque psoriasis. Topical roflumilast 0.3% cream, approved by the US FDA and Health Canada for use in adolescents and adults, has proven efficacy and tolerability. It is non-steroidal, administered once-daily, and highly potent, with a unique delivery formulation. It can be used on most body areas, including the sensitive intertriginous regions and face. Herein, we review the safety and efficacy of roflumilast 0.3% cream, as demonstrated in clinical trials.PMID:37734074 (Source: Skin Therapy Letter)
Source: Skin Therapy Letter - September 21, 2023 Category: Dermatology Authors: Ashley O'Toole Melinda Gooderham Source Type: research
A Practical Guide to Advanced Topical Drug Delivery Systems in Dermatology
Skin Therapy Lett. 2023 Sep;28(5):5-11.ABSTRACTDermatological diseases such as atopic dermatitis, acne, and psoriasis result in significant morbidity and decreased quality of life. The first line of treatment for such diseases is often topical medications. While topical delivery allows active drug to be delivered directly to the target site, the skin is a virtually impermeable barrier that impedes delivery of large molecules. Thus, the formulation and delivery system are integral elements of topical medications. Patients also have preferences for the properties of topical formulations and these preferences can positively o...
Source: Skin Therapy Letter - September 21, 2023 Category: Dermatology Authors: Andrei Metelitsa Isabelle Delorme Daniel O'Sullivan Rami Zeinab Mark Legault Melinda Gooderham Source Type: research
Topical Roflumilast for Plaque Psoriasis
Skin Therapy Lett. 2023 Sep;28(5):1-4.ABSTRACTRoflumilast is a highly selective phosphodiesterase-4 inhibitor for the treatment of plaque psoriasis. Topical roflumilast 0.3% cream, approved by the US FDA and Health Canada for use in adolescents and adults, has proven efficacy and tolerability. It is non-steroidal, administered once-daily, and highly potent, with a unique delivery formulation. It can be used on most body areas, including the sensitive intertriginous regions and face. Herein, we review the safety and efficacy of roflumilast 0.3% cream, as demonstrated in clinical trials.PMID:37734074 (Source: Skin Therapy Letter)
Source: Skin Therapy Letter - September 21, 2023 Category: Dermatology Authors: Ashley O'Toole Melinda Gooderham Source Type: research
A Practical Guide to Advanced Topical Drug Delivery Systems in Dermatology
Skin Therapy Lett. 2023 Sep;28(5):5-11.ABSTRACTDermatological diseases such as atopic dermatitis, acne, and psoriasis result in significant morbidity and decreased quality of life. The first line of treatment for such diseases is often topical medications. While topical delivery allows active drug to be delivered directly to the target site, the skin is a virtually impermeable barrier that impedes delivery of large molecules. Thus, the formulation and delivery system are integral elements of topical medications. Patients also have preferences for the properties of topical formulations and these preferences can positively o...
Source: Skin Therapy Letter - September 21, 2023 Category: Dermatology Authors: Andrei Metelitsa Isabelle Delorme Daniel O'Sullivan Rami Zeinab Mark Legault Melinda Gooderham Source Type: research
Topical Roflumilast for Plaque Psoriasis
Skin Therapy Lett. 2023 Sep;28(5):1-4.ABSTRACTRoflumilast is a highly selective phosphodiesterase-4 inhibitor for the treatment of plaque psoriasis. Topical roflumilast 0.3% cream, approved by the US FDA and Health Canada for use in adolescents and adults, has proven efficacy and tolerability. It is non-steroidal, administered once-daily, and highly potent, with a unique delivery formulation. It can be used on most body areas, including the sensitive intertriginous regions and face. Herein, we review the safety and efficacy of roflumilast 0.3% cream, as demonstrated in clinical trials.PMID:37734074 (Source: Skin Therapy Letter)
Source: Skin Therapy Letter - September 21, 2023 Category: Dermatology Authors: Ashley O'Toole Melinda Gooderham Source Type: research
A Practical Guide to Advanced Topical Drug Delivery Systems in Dermatology
Skin Therapy Lett. 2023 Sep;28(5):5-11.ABSTRACTDermatological diseases such as atopic dermatitis, acne, and psoriasis result in significant morbidity and decreased quality of life. The first line of treatment for such diseases is often topical medications. While topical delivery allows active drug to be delivered directly to the target site, the skin is a virtually impermeable barrier that impedes delivery of large molecules. Thus, the formulation and delivery system are integral elements of topical medications. Patients also have preferences for the properties of topical formulations and these preferences can positively o...
Source: Skin Therapy Letter - September 21, 2023 Category: Dermatology Authors: Andrei Metelitsa Isabelle Delorme Daniel O'Sullivan Rami Zeinab Mark Legault Melinda Gooderham Source Type: research
Topical Roflumilast for Plaque Psoriasis
Skin Therapy Lett. 2023 Sep;28(5):1-4.ABSTRACTRoflumilast is a highly selective phosphodiesterase-4 inhibitor for the treatment of plaque psoriasis. Topical roflumilast 0.3% cream, approved by the US FDA and Health Canada for use in adolescents and adults, has proven efficacy and tolerability. It is non-steroidal, administered once-daily, and highly potent, with a unique delivery formulation. It can be used on most body areas, including the sensitive intertriginous regions and face. Herein, we review the safety and efficacy of roflumilast 0.3% cream, as demonstrated in clinical trials.PMID:37734074 (Source: Skin Therapy Letter)
Source: Skin Therapy Letter - September 21, 2023 Category: Dermatology Authors: Ashley O'Toole Melinda Gooderham Source Type: research
A Practical Guide to Advanced Topical Drug Delivery Systems in Dermatology
Skin Therapy Lett. 2023 Sep;28(5):5-11.ABSTRACTDermatological diseases such as atopic dermatitis, acne, and psoriasis result in significant morbidity and decreased quality of life. The first line of treatment for such diseases is often topical medications. While topical delivery allows active drug to be delivered directly to the target site, the skin is a virtually impermeable barrier that impedes delivery of large molecules. Thus, the formulation and delivery system are integral elements of topical medications. Patients also have preferences for the properties of topical formulations and these preferences can positively o...
Source: Skin Therapy Letter - September 21, 2023 Category: Dermatology Authors: Andrei Metelitsa Isabelle Delorme Daniel O'Sullivan Rami Zeinab Mark Legault Melinda Gooderham Source Type: research
Topical Roflumilast for Plaque Psoriasis
Skin Therapy Lett. 2023 Sep;28(5):1-4.ABSTRACTRoflumilast is a highly selective phosphodiesterase-4 inhibitor for the treatment of plaque psoriasis. Topical roflumilast 0.3% cream, approved by the US FDA and Health Canada for use in adolescents and adults, has proven efficacy and tolerability. It is non-steroidal, administered once-daily, and highly potent, with a unique delivery formulation. It can be used on most body areas, including the sensitive intertriginous regions and face. Herein, we review the safety and efficacy of roflumilast 0.3% cream, as demonstrated in clinical trials.PMID:37734074 (Source: Skin Therapy Letter)
Source: Skin Therapy Letter - September 21, 2023 Category: Dermatology Authors: Ashley O'Toole Melinda Gooderham Source Type: research
A Practical Guide to Advanced Topical Drug Delivery Systems in Dermatology
Skin Therapy Lett. 2023 Sep;28(5):5-11.ABSTRACTDermatological diseases such as atopic dermatitis, acne, and psoriasis result in significant morbidity and decreased quality of life. The first line of treatment for such diseases is often topical medications. While topical delivery allows active drug to be delivered directly to the target site, the skin is a virtually impermeable barrier that impedes delivery of large molecules. Thus, the formulation and delivery system are integral elements of topical medications. Patients also have preferences for the properties of topical formulations and these preferences can positively o...
Source: Skin Therapy Letter - September 21, 2023 Category: Dermatology Authors: Andrei Metelitsa Isabelle Delorme Daniel O'Sullivan Rami Zeinab Mark Legault Melinda Gooderham Source Type: research
Topical Roflumilast for Plaque Psoriasis
Skin Therapy Lett. 2023 Sep;28(5):1-4.ABSTRACTRoflumilast is a highly selective phosphodiesterase-4 inhibitor for the treatment of plaque psoriasis. Topical roflumilast 0.3% cream, approved by the US FDA and Health Canada for use in adolescents and adults, has proven efficacy and tolerability. It is non-steroidal, administered once-daily, and highly potent, with a unique delivery formulation. It can be used on most body areas, including the sensitive intertriginous regions and face. Herein, we review the safety and efficacy of roflumilast 0.3% cream, as demonstrated in clinical trials.PMID:37734074 (Source: Skin Therapy Letter)
Source: Skin Therapy Letter - September 21, 2023 Category: Dermatology Authors: Ashley O'Toole Melinda Gooderham Source Type: research
